Correction to “Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library”
Abstract
Page 2928. Abstract: “database of natural compounds”, should be replaced with “database of natural compounds and derivatives”. Page 2929. Line 5, right column, replace “Natural Compound” with “Natural Compound Derivative”. Page 2929. Line 7, right column: replace “natural compound library” with “library of natural compounds and derivatives”. Page 2929. Line 9, left column. Replace “traditional Chinese medicine (TCM) database” with “database of traditional Chinese medicines and derivatives”. Page 2929. Figure 2 legend: Change title from “Natural compounds···” to “Compounds···”. Page 2933. Experimental Section lines 1−2. Replace “natural ligand” with “ZINC”. Page 2933. Experimental section line 4: remove “natural ligand”. Page 2934. Left column, Virtual Screening and Binding Affinity Calculation section, line 2. Remove “natural”.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.